Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
Drugs
901 - 920 of 1,297 Results
-
-
In The Battle To Control Drug Costs, Old Patent Laws Get New Life
Health insurers and pharmacy benefit managers are exploring how two legal provisions 鈥 which have been on the books for decades 鈥 could bring down the price tags of certain prescription medications.聽
-
Congress Targets Misuse Of Hospice Drugs
In the bipartisan opioid bill headed to the president鈥檚 desk, hospice workers would be allowed to destroy patients鈥 unneeded opioids, reducing the risk that families misuse them.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 Some Things Old, Some Things New
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
-
VA Adding Opioid Antidote To Defibrillator Cabinets For Quicker Overdose Response
A project that started in a Boston Veterans Affairs facility will soon go nationwide. It puts naloxone, also known as Narcan, into emergency supplies cabinets throughout the VA system.
-
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there鈥檚 a twist involving an opioid treatment.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 (Almost) Live from Austin!
In this episode of KHN鈥檚 鈥淲hat the Health?鈥 Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Ollstein of Politico talk about how health issues will play in midterm elections, the Trump administration鈥檚 move that could penalize legal immigrants who use government aid programs, and other topics. Due to technical difficulties, the original discussion taped Sept. 27 at the 2018 Texas Tribune Festival could not be broadcast, so the panelists reconvened from Austin and Washington on Sept. 28.
-
Buried In Congress’ Opioid Bill Is Protection For Personal Drug Imports
The protection is a win for people who get their needed, legitimate drugs from overseas.
-
Readers And Tweeters Slice And Dice Precision Medicine, Step Therapy
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
Workers Overdose On The Job, And Employers Struggle To Respond
Despite the growing epidemic of Americans misusing opioids and overdosing on the job, many employers turn a blind eye to addiction within their workforce 鈥 ill-equipped or unwilling to confront an issue they are at a loss to handle.
By Jenny Gold -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
As States Try To Rein In Drug Spending, Feds Slap Down One Bold Medicaid Move
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren't proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
-
New Medicare Advantage Tool To Lower Drug Prices Puts Crimp In Patients’ Choices
Federal officials are allowing the private insurance plans to use 鈥渟tep therapy鈥 for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
By Susan Jaffe -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Insurer To Purdue Pharma: We Won’t Pay For OxyContin Anymore
Embattled drugmaker Purdue Pharma defends OxyContin as some insurers are dropping the drug in favor of other abuse-deterrent opioid painkillers.
-
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Insulin’s Steep Price Leads To Deadly Rationing
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn't afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
-
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma鈥檚 pricing.
By Emily Kopp and Jay Hancock